March 29, 2024
“Shares of Viking Therapeutics (NASDAQ: VKTX) are up about 275% in 2023, but analysts on Wall Street think it isn’t finished climbing yet. The consensus price target on the clinical-stage biotech stock suggests a 47% gain could be up ahead…. Shares of Iovance Biotherapeutics (NASDAQ: IOVA) have more… Continue Reading…
Recent Comments